People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 6, 2026, 09:07 GMT-04
Novo-Nordisk-Data
Read full article →